Genmab A/S
The answer first
Does Genmab beat the market?
Yes, Genmab has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 71% of Nordic stocks
- Quality75
- Value11
- Trend98
No. 38 of 195 in healthcare
Expectations in the price
High expectations
For the share to return about 9% a year from today's price, the cash Genmab keeps must grow about 15% a year for 10 years.
Max for seven days
Follow Genmab with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Genmab
Your first answer is free, no account needed.
Do you own Genmab, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Genmab and a few more. Free, no card.
Super Stock+44.6%In short
- Genmab has risen 82.5% over the past year, including dividends.
- Overall, Genmab ranks better than 71% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 64.5%. The price is 10.6% below its peak now.
What do analysts think of Genmab?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 71% of Nordic stocks.
No. 38 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 70 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.83
- Asset turnoverSales divided by everything the company owns0.33
- Return on equityProfit divided by equity+11.5%
- Cash conversionOperating cash flow divided by profit1.20
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 132 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity5.0
- P/SPrice divided by sales7.4
- P/EPrice divided by earnings43.7
- P/CFPrice divided by operating cash flow36.3
The ranking is built on P/E, P/B and P/S.
High Tailwind in the share price: it has risen more than most over the last year.
No. 6 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+62.5%
- 6 months+102.8%
- 9 months+79.0%
- 12 months+82.5%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Genmab
48 funds we follow own Genmab. The share is how much of the fund the stock makes up.
- Norway4
- Sweden35
- Denmark9
- 3 ETFs
- Sparindex INDEX OMX C25 KLDenmark · Sparindex11.1%
- Sparinvest INDEX OMX C25 KLDenmark · Sparinvest11.1%
- Sydinv Indeks Danmark A DKKDenmark · Sydinvest8.8%
- BIX Danske Aktier Indeks ADenmark · BIX7.0%
- BIX Danske Aktier Indeks Akk ADenmark · BIX7.0%
- Danske Invest Danmark IndeksDenmark · Danske Invest7.0%
- Xact KapitalforvaltningDenmark · XACT · ETF5.7%
- Nordnet Indeksfond Danmark ASweden · Nordnet5.7%
Show all 48
- HealthInvest Small & MicroCap Fund CSweden · HealthInvest4.0%
- HealthInvest Small & Mid Cap Healthcare ESweden · HealthInvest4.0%
- Levler MSCI Nordic by Xtrackers UCITS ETFSweden · Levler · ETF2.5%
- Alfred Berg Nordic Index R (SEK)Norway · Alfred Berg2.4%
- DNB Norden Indeks ANorway · DNB2.4%
- KLP AksjeNorden IndeksNorway · KLP2.1%
- Xact NordenSweden · XACT · ETF1.4%
- Wealth Inv I&T Nord AktLargeCaDenmark · Wealth Invest1.1%
- Handelsbanken Norden Ind Crit (A1 NOK)Sweden · Handelsbanken1.0%
- Handelsbanken Global Dynam 90 (A1 SEK)Sweden · Handelsbanken0.7%
- Eika SparNorway · Eika0.6%
- Simplicity NordenSweden · Simplicity0.4%
- Avanza EuropaSweden · Avanza0.2%
- SEB Europe Exposure B (SEK)Sweden · SEB0.1%
- Öhman Etisk Index EuropaSweden · Öhman0.1%
- Länsförsäkringar Europa IndexnäraSweden · Länsförsäkringar0.1%
- Skandia Europa ExponeringSweden · Skandia0.1%
- Swedbank Robur Access Edge Europe ASweden · Swedbank Robur0.1%
- Swedbank Robur Access Europa ASweden · Swedbank Robur0.1%
- Wealth Invest SGA Globale AktDenmark · Wealth Invest0.1%
- SEB Active 80 ASweden · SEB0.1%
- Handelsbanken Developed Markets Index Criteria (A1 SEK)Sweden · Handelsbanken0.1%
- Lysa Global Aktier Hållbar BSweden · Lysa0.1%
- SEB Active 55 ASweden · SEB0.1%
- Länsförsäkringar Global KlimatIndexSweden · Länsförsäkringar0.0%
- Avanza GlobalSweden · Avanza0.0%
- Handelsbanken Global Index Crit (A1 NOK)Sweden · Handelsbanken0.0%
- SEB Active 30 ASweden · SEB0.0%
- AP7 AktiefondSweden · AP70.0%
- Handelsbanken Global Index Core (A1 SEK)Sweden · Handelsbanken0.0%
- Lysa Aktier CSweden · Lysa0.0%
- Länsförsäkringar Global IndexnäraSweden · Länsförsäkringar0.0%
- PLUS Global IndexSweden · PLUS0.0%
- SEB Active 20 ASweden · SEB0.0%
- SPP Aktiefond EuropaSweden · SPP0.0%
- Storebrand Europa C NOKSweden · Storebrand0.0%
- Öhman Global Marknad Hållbar ASweden · Öhman0.0%
- Länsförsäkringar Sparmål 2030Sweden · Länsförsäkringar0.0%
- Skandia Global Exponering ASweden · Skandia0.0%
- Skandia SMART FörsiktigSweden · Skandia0.0%
From the funds' latest known holdings.
About Genmab
Genmab A/S is a company in healthcare, listed on Nasdaq Copenhagen. The share trades in DKK. It has around 3,200 employees.
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.


See the full analysis of Genmab.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card